Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma

BACKGROUND: The clinical outcomes of hepatocellular carcinoma (HCC) patients who receive transarterial chemoembolization (TACE) and immunotherapy are not well characterized. The present study evaluates the safety and efficacy of TACE in combination with immune checkpoint inhibitor treatment for unre...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jin-Xing, Chen, Pei, Liu, Sheng, Zu, Qing-Quan, Shi, Hai-Bin, Zhou, Chun-Gao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979422/
https://www.ncbi.nlm.nih.gov/pubmed/35388358
http://dx.doi.org/10.2147/JHC.S358658

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979422/
https://www.ncbi.nlm.nih.gov/pubmed/35388358
http://dx.doi.org/10.2147/JHC.S358658

Ejemplares similares